|

WATCH OUR LATEST VIDEOS

OUR CHAIRS INVITE YOU TO JOIN

Alfredo Addeo

Alfredo Addeo, MD, is a Consultant Medical Oncologist at the University Hospital of Geneva, Switzerland. He is the author of numerous national and international peer-reviewed publications in renowned scientific journals, including first- and last-author publications in the Journal of Clinical Oncology, Annals of Oncology and Lancet Oncology. He has acted as a reviewer for several international scientific journals, including Journal of Thoracic Oncology and JAMA Oncology, and is an associate editor for Frontiers in Thoracic Oncology and guest editor for Precision Cancer Medicine. Dr. Addeo is an active ESMO member and a member of the EORTC lung group. He actively participates in ETOP (European Thoracic Oncology Platform) and SAKK (the Swiss Group for Clinical Cancer Research) and is a researcher and co-investigator of several national and international studies.

Don’t miss the WestWind podcast with Dr. Jack West hosting Dr. Addeo to learn more about his path and challenges from Italy over UK to Switzerland.

more about Dr. Addeo

He was trained and received his doctorate in Italy from the University School of Medicine in Turin. After his residency, he worked for another 4 years in Turin as a Consultant Oncologist. From 2010 to 2017 he further sharpened his interest in thoracic malignancies in the UK. First at the United Lincolnshire Hospital NHS Trust and later at the University Hospital Bristol, Dr. Addeo also took on the role as senior lecturer in Medical Oncology. As an active member of the NCRI Mesothelioma Working Group, he has also participated in several national and international NCRI drug studies. Dr. Addeo’s research continues to focus on drug development and translational aspects of precision medicine, immunotherapy and side effects, particularly in small and non-smal cell lung cancer (NSCLC) as well as melanoma.

During his time in the UK, Dr. Addeo developed further research interests in liquid biopsies, ctDNA analysis, and tumor mutation burden (TMB) in blood samples. For his research activities in this field he received a grant for a research proposal, which is still ongoing.

In September 2017, Dr. Addeo moved to Geneva, where he received the post of medical oncologist with a primary responsibility for Thoracic Malignancies.

Solange Peters

Solange Peters, MD, PhD, is Professor and chair of Medical Oncology as well as the Thoracic Malignancies programme in the department of oncology at the University Hospital of Lausanne, Switzerland. She has authored numerous peer-reviewed manuscripts and book chapters, and serves as deputy editor of the Journal of Thoracic Oncology, and on the editorial board of several other oncology journals. Professor Peters is active in the educational programs of the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC), notably working as the current editor of the ESMO lung cancer clinical practice guidelines. She is the Chair of ESMO Women for Oncology Committee, and she is the youngest ESMO President-elect ever, for a mandate in 2020-2021. She was also a member of the IASLC board of directors, and acts as vice president of the Swiss Group for Clinical Cancer Research lung group. She received both her doctorate in medicine and PhD from the University Hospital of Lausanne, Switzerland. After completing her clinical education in medical oncology and molecular biology in Switzerland and Italy, Professor Peters has specialized in thoracic tumors, lung cancer, and pleural tumors.

more about Prof. Peters

Professor Peters is currently in charge of teaching and patient care in the area of Thoracic Malignancies in the department of oncology of Lausanne University, where she is building a translational programme in collaboration with the molecular oncology laboratory directed by Dr. Hanahan at the Swiss Federal Institute of Technology in Lausanne and the Ludwig Institute. Professor Peters’ main field of interest is new biomarker discovery and validation in preclinical and clinical settings. She is also strongly involved and interested in multimodality trial building for locally advanced non-small cell lung cancer (NSCLC), as well as cancer immunotherapy.

Professor Peters’ current research projects are focused on multimodality stage III NSCLC treatment strategies, immunotherapy in limited small cell lung cancer and advanced thymic malignancies, advanced NSCLC, ALK inhibitors, HER2 inhibitors, as well as immunotherapy combinations and new immunomodulating treatments across thoracic malignancies. She acts as the local principal investigator (PI) for lung trials opened at Lausanne Cancer Centre, focused on phase I predictive biomarkers and thoracic malignancies immunotherapy, and is a co-PI of several other trials. Additionally, she acts as the scientific coordinator of the European Thoracic Oncology Platform (ETOP).


Our Speakers

Agenda 2020

Following the great success of the first International Lung Cancer Summit (ILCS), we are delighted to invite you to the 2nd International Lung Cancer Summit (ILCS) in Geneva. Similar to 2019, the ILCS will showcase recent discoveries and advances performed towards the treatment of lung cancer. The conference will leverage digital channels to provide with an exceptional outreach and opportunity for delegates from Medical Offices, Universities and Institutes to interact with world-class Medical Oncologists and Industry Professionals working in the field of lung cancer treatment and research. The ILCS constitutes an ideal platform to share knowledge and seamless treatment procedures with our local and international speakers from the USA, Spain, France, UK and Switzerland.
TIME AGENDA SPEAKER
(Central European Time)    
13.00 Welcome & introduction S. Peters &
A. Addeo
13.10 The power of social media in Oncology: what we can learn from our virtual peers G. Morgan
13.30 Treatment standards in non-oncogene addicted NSCLC before COVID19 M. Pérol
13.50 How can we treat patients with lung cancer during the SARS-CoV-2 pandemic G. Banna
14.10 COVID19 & lung cancer: treatment & outcomes from a Spanish cohort A. Calles
14.30 Radiotherapy in lung cancer during the COVID-19 era A. Durham
14.50 Mesothelioma: new therapeutic strategies and future perspectives for a difficult disease with a heavy social burden A. Curioni
15.10 Break  
15.40 Small cell lung cancer (SCLC): Treatment challenges and a glimpse into the development of new targets S. Liu
16.00 Personalized Medicine with IO: can we tailor immunotherapy options to patients? J. Bauml
16.20 Actionable mutations on the horizon: up and coming agents in targeted therapies C. Rolfo
16.40 Tailoring targeted therapies: what TKI is suitable for what patient? H. West
17.00 Integrating immunotherapy into localized NSCLC S. Patel
17.20 Final Questions and Wrap Up A. Addeo & S. Peters

 

Confirmed accreditation of virtual conference by

SWISS SOCIETY OF MEDICAL ONCOLOGY (SSMO • SSOM • SGMO)

with 5 CME credits for all online participants

 

 

 

LOCATION

online here at
lungcancersummit.org

 

 

 

 

Follow us on Twitter

In the wake of #ADAURA trial, what will your practice be for molecular testing in patients with resected stage IB-IIIA NSCLC?

Please amplify as needed in the comments.

#LCSM

@VPrasadMDMPH @VivekSubbiah @DSolit @GeneCollector @Dr_R_Kurzrock It has been a pleasure. Thanks to you @VPrasadMDMPH for letting me be part of this. Thanks to @VivekSubbiah @DSolit @GeneCollector @Dr_R_Kurzrock for their thoughtful arguments. Life would be more boring if we all agreed on everything.

Good news for ALK patients: Lorlatinib Significantly Improves PFS vs crizotinib in untreated #ALK #NSCLC. This is only the Press release. Looking forward to seeing the numbers and to compare with Alectinib in ALEX. ⁦@OncoAlert⁩ #LCSM https://www.businesswire.com/news/home/20200805005244/en/LORBRENA%C2%AE-lorlatinib-Significantly-Improves-Progression-Free-Survival-First-Line

Your pt w/adv EGFR mut+ NSCLC responded on 1L osimertinib x21 mos, now multifocal PD in chest & new liver mets. Repeat Bx shows orig EGFR mut'n, no new target. No trial available, so you decide to transition to chemo. No h/o brain mets.

Continue osi if can get it covered?

#LCSM

Attention fellows and trainees - I know there's been fewer educational opportunities due to #COVID19. I am doing a webinar on lung cancer on August 11 at 6 PM EST with @CCO_Oncology. Would love to have as many trainees that are interested register here https://wendyballard.my.webex.com/wendyballard.my/j.php?RGID=rab348d35e2080cbc576ac5c3b93fb0f4

Load More...

OUR PARTNERS

For sponsoring requests, please contact us at sponsoring@lungcancersummit.org